TLOG Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
TetraLogic Pharmaceuticals Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -99.90% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| TLOG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 4.3% | 1.6% |
| 1Y | n/a | 18.8% | 32.3% |
Return vs Industry: Insufficient data to determine how TLOG performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how TLOG performed against the US Market.
Price Volatility
| TLOG volatility | |
|---|---|
| TLOG Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: TLOG's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine TLOG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | n/a | www.tetralogicpharma.com |
TetraLogic Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases. It has two clinical-stage product candidates in development, such as birinapant and SHAPE. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases-mimetic, which leads to apoptosis or cell-death in damaged cells.
TetraLogic Pharmaceuticals Corporation Fundamentals Summary
| TLOG fundamental statistics | |
|---|---|
| Market cap | US$24.00 |
| Earnings (TTM) | -US$40.72m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs TLOG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TLOG income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$40.72m |
| Earnings | -US$40.72m |
Last Reported Earnings
Sep 30, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did TLOG perform over the long term?
See historical performance and comparison